Innovative Partnership Unites Syantra and Alamo Breast Cancer Foundation to Revolutionize Detection and Care

Syantra and Alamo Breast Cancer Foundation: A Groundbreaking Partnership

In a significant step towards enhancing breast cancer detection and treatment, Syantra, Inc., a pioneering biotechnology company, has announced a partnership with the Alamo Breast Cancer Foundation (ABCF). This collaboration is the first of its kind, as it merges innovative technology with a commitment to improving healthcare accessibility for women across demographics.

Founded in Calgary, Syantra has developed a revolutionary platform designed to change the landscape of cancer detection. It employs advanced methodologies to facilitate earlier diagnosis of breast cancer, particularly for women with dense breast tissue—a condition affecting over 43% of women aged 40 and over. Understanding the dire need for more effective and accessible screening methods, both organizations aim to bridge gaps in the current healthcare framework.

ABCF, established in 1993 by breast cancer survivors dedicated to advocacy and community outreach, complements Syantra's technological efficacy with its extensive grassroots network. Their united mission strives to ensure that quality care and latest detection technologies reach underserved populations who often face barriers to accessing traditional healthcare solutions, such as mammograms.

The partnership will encompass targeted funding initiatives, legislative advocacy, and significant in-kind contributions from ABCF's leadership. By leveraging Syantra's Onco-ID Breast platform, which utilizes the body’s immune signals to identify cancer signatures through a unique blend of gene expression analysis, the aim is to promote early detection of malignancies that may elude standard mammographic procedures.

As Syantra's CEO Rob Lozuk highlighted, this collaboration marks an important milestone by joining forces with the first advocacy group dedicated to breast cancer. His excitement underscores the potential of this partnership to mobilize resources and raise awareness about screening options that are critical for women’s health. “Having ABCF in our corner with their expertise on advocacy significantly amplifies our reach and effectiveness,” he stated.

In addition to enhancing early detection methods, this partnership will drive a clinical study at the Mays Cancer Center in San Antonio, Texas, aiming to gather diverse datasets and encourage the integration of the Onco-ID technology into clinical practice. The partnership hopes to inform insurance reimbursement policies, paving the way for broader implementation of these advanced diagnostic tools in healthcare settings.

“Expanding our capacity to deliver life-saving testing and treatment across age groups and geographies is vital,” noted ABCF Board Member Jerry Worden. “By collaborating with Syantra, we aspire to refine testing methods that enhance the detection of smaller tumors and consequently increase survival rates.”

Syantra’s innovative platform, based on proprietary software and machine learning algorithms, promises to facilitate the precision medicine needed for individualized patient care. As both entities lead the charge towards transforming cancer care through awareness and advocacy, it is clear that their combined efforts have the potential to positively impact countless lives.

This partnership is not only a beacon of hope for affected individuals but also a stepping stone towards embracing advocacy in scientific endeavors. By effectively merging technological innovation with community outreach, Syantra and ABCF are poised to create a new standard in the fight against breast cancer, making strides towards accessible and quality healthcare for all women.

For more information about Syantra, visit syantra.com, and for ABCF, see alamobreastcancer.org.